Regarding overall cancer risk, a French population-based study from 2023 on pediatric-onset IBD [17] reported an HR from 6.1 to 7.4 in patients under therapy with anti-TNFα and combination therapy. This evidence concerns the gene TNF and inflammatory bowel disease.